FASLG and urinary bladder cancer: Treatment with cisplatin increased the level of the membrane-bound Fas ligand (FasL) in the TTC (833 K, SuSa and GCT27), while no FasL could be detected in the bladder cancer cell lines (Fig. 4A, B).